top of page
NEWS and PRESS RELEASES
02 May 2023
CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal
Read more
10 December 2021
CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
Read more
23 February 2022
Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC
Read more
17 August 2021
Widely available anti-allergy azelastine nasal spray poised to revolutionize COVID-19 management
Read more
04 July 2022
CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2
Read more
03 February 2022
Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of
SARS-CoV-2
Read more
14 June 2021
CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
Read more
bottom of page